利福霉素衍生物对非结核分枝杆菌的活性，包括对大环内酯类/阿米卡星耐药的临床分离株
Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.
作者信息
Kim Dae Hun, Kim Su-Young, Huh Hee Jae, Lee Nam Yong, Koh Won-Jung, Jhun Byung Woo
机构信息
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
出版信息
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02611-20. Epub 2021 Mar 8.
Abstract
We evaluated the activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs against all NTM species, including complex, , and Rifabutin also had effective activity against macrolide- and aminoglycoside-resistant NTM isolates. Rifabutin could be worth considering as a therapeutic option for NTM disease, particularly drug-resistant disease.
摘要
我们评估了利福霉素衍生物，包括利福平、利福喷汀、利福昔明和利福布汀，对临床非结核分枝杆菌（NTM）分离株的活性。在利福霉素衍生物中，利福布汀对所有NTM菌种，包括复合群、 和 ，显示出最低的最低抑菌浓度（MIC）。利福布汀对大环内酯类和氨基糖苷类耐药的NTM分离株也具有有效的活性。利福布汀可能值得作为NTM疾病，特别是耐药疾病的一种治疗选择来考虑。
相似文献
1
Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.利福霉素衍生物对非结核分枝杆菌的活性，包括对大环内酯类/阿米卡星耐药的临床分离株
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02611-20. Epub 2021 Mar 8.
2
Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.呼吸道常见临床相关非结核分枝杆菌分离株的抗菌药敏和最小抑菌浓度分布。
Ann Med. 2022 Dec;54(1):2500-2510. doi: 10.1080/07853890.2022.2121984.
3
activity of fidaxomicin against nontuberculosis mycobacteria.对非结核分枝杆菌的 fidaxomicin 活性。
J Med Microbiol. 2022 Jun;71(6). doi: 10.1099/jmm.0.001549.
4
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.贝达喹啉和德拉马尼对非结核分枝杆菌（包括大环内酯类耐药临床分离株）的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
5
In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.氯法齐明治疗非结核分枝杆菌肺病的体外活性及临床疗效
J Clin Med. 2021 Oct 3;10(19):4581. doi: 10.3390/jcm10194581.
6
Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.唑烷酮类药物对非结核分枝杆菌的活性，包括大环内酯类耐药的临床分离株。
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0230620. doi: 10.1128/AAC.02306-20.
7
Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.依拉环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0068922. doi: 10.1128/aac.00689-22. Epub 2022 Aug 9.
8
Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.2016年至2020年韩国一家三级医院非结核分枝杆菌的分离与药敏分析
Tuberc Respir Dis (Seoul). 2023 Jan;86(1):47-56. doi: 10.4046/trd.2022.0115. Epub 2022 Dec 8.
9
Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria.新型苯并咪唑类药物 SPR719 对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01503-18. Print 2018 Nov.
10
GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.GenoType NTM-DR 检测试剂盒鉴定鸟分枝杆菌复合群和脓肿分枝杆菌及检测克拉霉素和阿米卡星耐药性的性能评估。
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00516-19. Print 2019 Aug.
引用本文的文献
1
Detection of a Mixed-Strain Infection with Drug- and Multidrug-Resistant Subspecies in a Dog with Generalized Lymphadenomegaly.一只患有全身性淋巴结肿大的犬体内药物及多重耐药亚种混合菌株感染的检测
Antibiotics (Basel). 2025 Apr 19;14(4):416. doi: 10.3390/antibiotics14040416.
2
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物：来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
3
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
4
Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.非结核分枝杆菌病：新型候选药物和再利用药物研发的进展与突破。
Front Cell Infect Microbiol. 2023 Oct 2;13:1243457. doi: 10.3389/fcimb.2023.1243457. eCollection 2023.
5
Risk factors for microbiological persistence after 6 months of treatment for and its impact on the drug-resistance profile.治疗6个月后微生物持续存在的危险因素及其对耐药谱的影响。
Microbiol Spectr. 2023 Sep 25;11(5):e0080523. doi: 10.1128/spectrum.00805-23.
6
Activity of Pretomanid against Nontuberculous Mycobacteria.普瑞曼尼对非结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0181021. doi: 10.1128/AAC.01810-21. Epub 2021 Nov 1.
7
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.阻断细菌萘氢醌氧化和 ADP-核糖基化可提高利福霉素类药物对脓肿分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
本文引用的文献
1
In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens.脓肿分枝杆菌复合体的体外药敏试验及标准化治疗方案的可行性。
J Antimicrob Chemother. 2021 Mar 12;76(4):973-978. doi: 10.1093/jac/dkaa520.
2
Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.利福布汀对脓肿分枝杆菌的细胞内和细胞外形式均具有杀菌作用。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00363-20.
3
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.非结核分枝杆菌肺病治疗：美国胸科学会/欧洲呼吸学会/欧洲临床微生物学和传染病学会/美国感染病学会临床实践指南。
Clin Infect Dis. 2020 Aug 14;71(4):905-913. doi: 10.1093/cid/ciaa1125.
4
Rifabutin Is Active against Mycobacterium abscessus in Mice.利福布汀对小鼠中的脓肿分枝杆菌有效。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
5
Repositioning rifamycins for Mycobacterium abscessus lung disease.重新定位利福霉素类药物治疗脓肿分枝杆菌肺病。
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
6
GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.GenoType NTM-DR 检测试剂盒鉴定鸟分枝杆菌复合群和脓肿分枝杆菌及检测克拉霉素和阿米卡星耐药性的性能评估。
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00516-19. Print 2019 Aug.
7
pulmonary disease: individual patient data meta-analysis.肺病：个体患者数据荟萃分析。
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.01991-2018. Print 2019 Jul.
8
Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007-2016.2007-2016 年韩国非结核分枝杆菌感染的流行病学研究。
Emerg Infect Dis. 2019 Mar;25(3):569-572. doi: 10.3201/eid2503.181597.
9
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.利福布汀与克拉霉素、亚胺培南和替加环素联合应用对复合体的协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.
10
and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.并评估亚胺培南联合利福布汀和阿维巴坦对脓肿分枝杆菌的胞内活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00623-18. Print 2018 Aug.
Zotero 插件